PolyNovo and Vysarn Post Double-Digit FY26 Earnings Growth

The Quick Take

• PolyNovo posted double-digit revenue growth and positive profit for FY2026 as manufacturing scales globally
• Vysarn delivered double-digit revenue and profit gains for FY2026 on national expansion strategy
• Both Australian small-caps demonstrate earnings quality improvement alongside top-line growth

Two Australian listed companies delivered strong FY2026 earnings results, with medtech firm PolyNovo reporting double-digit revenue growth and positive profit as its manufacturing expansion and global market reach supported its ambitions in the wound-management technology sector. Simultaneously, water services company Vysarn reported double-digit gains in both revenue and profit for FY2026, attributing the performance to continued execution on its national growth strategy. Both companies represent the small-to-mid-cap Australian growth cohort where earnings quality improvement alongside revenue growth is the key valuation re-rating catalyst.

PolyNovo success in medtech reflects a broader Australian biomedical device sector trend where domestic R&D platforms are gaining traction in international markets, particularly in wound care and dermal substitute applications. Vysarn national expansion within water services positions it within Australia infrastructure services sector, which benefits from sustained government capital works spending and resources sector activity across Western Australia and Queensland. Both earnings reports arriving simultaneously suggest a healthy FY26 reporting season for Australian small-caps that had guided conservatively and have now exceeded those conservative expectations.

Watch PolyNovo next half-year revenue guidance for indication of whether international market penetration is accelerating, which would be the key valuation re-rating trigger for the medtech name. For Vysarn, contract pipeline announcements and any extension of government infrastructure mandates will signal the sustainability of the FY26 growth. The macro variable for both companies is Australian business investment confidence: a softening capex environment in resources or infrastructure would disproportionately affect Vysarn, while PolyNovo international revenue diversification provides a natural hedge against domestic economic softening.

Synthesized from 2 sources.